Another crazy and profitable year in biotech investing was captured 140 characters at a time.
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
Though the S&P 500 has rallied to record highs over the past three weeks, analysts predict markets will continue to climb through to year's end.